Related references
Note: Only part of the references are listed.Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
Mohamed Ismail Abdul Aziz et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
Bingnan Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer
Rin Ogiya et al.
CLINICAL BREAST CANCER (2019)
Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore
Sil-ling Pruis et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2019)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
S. -A. Im et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
H. S. Rugo et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2018)
Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
Ping-Tee Tan et al.
BMC CANCER (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
Real world patient- and caregiver-reported outcomes in advanced breast cancer
V Lambert-Obry et al.
CURRENT ONCOLOGY (2018)
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2-Advanced or Metastatic Breast Cancer: A US Payer Perspective
Rohit Mistry et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers
Yoon-Sim Yap et al.
NPJ BREAST CANCER (2018)
Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain
Elena Galve-Calvo et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2018)
Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis
J. Raphael et al.
EUROPEAN JOURNAL OF CANCER (2017)
Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer
H. Mamiya et al.
ANNALS OF ONCOLOGY (2017)
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
K. Matter-Walstra et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Ten-year survival in women with primary stage IV breast cancer
Lee Guek Eng et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival
Ann H. Partridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Share Paper
